rising prevalence of genetic blood disorders such as sickle cell disease and beta-thalassemia, along with rapid progress in gene and cell-based therapies. The market is valued at USD 9.67 billion in 2025 and is expected to reach USD 20.50 billion by 2034, growing at a CAGR of 8.75% from 2026 to 2034.
Increasing Global Disease Burden Accelerating Market Growth
The growing number of patients...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek